The DYNLT1 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the NCI-H1975 human lung adenocarcinoma cell line, engineered for loss-of-function studies of the DYNLT1 gene. This product provides a heterogeneous pool of edited cells lacking functional DYNLT1 protein, enabling robust investigation of DYNLT1-dependent processes without clonal selection artifacts. The polyclonal format preserves genetic diversity while ensuring efficient target-gene disruption across the population.
The parental NCI-H1975 cell line is a well-characterized model of non-small cell lung cancer (NSCLC), derived from a female patient with lung adenocarcinoma harboring EGFR L858R/T790M mutations, which confer constitutive kinase activity and resistance to first-generation EGFR inhibitors. These cells exhibit typical epithelial morphology and serve as a clinically relevant platform for studying oncogenic signaling, drug resistance, and tumor cell biology. The EGFR mutant background makes NCI-H1975 cells particularly valuable for dissecting mechanisms of targeted therapy resistance and metastatic progression in lung adenocarcinoma.
DYNLT1 (Tctex-1) encodes a non-catalytic accessory subunit of the cytoplasmic dynein complex, a microtubule-based motor protein responsible for retrograde transport of diverse cargoes, including vesicles, organelles, and signaling molecules. Beyond its transport role, DYNLT1 interacts directly with Bcl-2 family proteins such as Bcl-2 and Bim, thereby regulating the intrinsic apoptotic pathway. Under stress conditions, DYNLT1 can sequester Bim, preventing caspase activation, or modulate Bcl-2??s anti-apoptotic function. DYNLT1 also associates with dynein intermediate chain (DYNC1I) and dynein heavy chain (DYNC1H) within the motor complex, linking cargo adaptors to the force-generating subunit. Upstream signals, including cellular stress and transcriptional regulators of dynein components, control DYNLT1 expression and localization, while its downstream effects influence apoptotic signaling, mitotic spindle organization, and intracellular trafficking pathways.
In the NCI-H1975 background, DYNLT1 disruption provides unique insights into how dynein-dependent transport intersects with EGFR-driven oncogenesis and apoptosis evasion. Given the EGFR mutant status, these knockout cells enable researchers to dissect DYNLT1??s role in modulating Bcl-2 family-mediated survival signals that may contribute to drug resistance. Additionally, loss of DYNLT1 can impair retrograde trafficking of signaling endosomes, potentially altering EGFR turnover and downstream signaling. The polyclonal knockout population allows assessment of heterogeneous responses to apoptotic stimuli, migration cues, and cytoskeletal reorganization, making it a powerful tool for studying the molecular cross-talk between microtubule motors and cancer cell fate.
This knockout product is ideally suited for a range of functional assays, including co-immunoprecipitation to study dynein complex integrity, live-cell imaging for tracking organelle transport, Annexin V-based apoptosis analyses to evaluate cell death sensitivity, and Transwell migration/invasion assays to probe metastatic potential. Immunofluorescence microscopy can reveal changes in microtubule organization or cargo distribution, while flow cytometry enables cell cycle and death profiling. Western blotting confirms DYNLT1 loss and altered expression of interacting partners such as Bcl-2 and Bim. These DYNLT1 knockout cells thus serve as a robust system for investigating intracellular transport defects, caspase cascade regulation, and the development of therapeutic strategies targeting dynein-mediated processes in lung adenocarcinoma. For further technical assistance, please contact Ascent Research to discuss your specific experimental needs.
